Functional Antagonism of Junctional Adhesion Molecule-A (JAM-A), Overexpressed in Breast Ductal Carcinoma In Situ (DCIS), Reduces HER2-Positive Tumor Progression

SIMPLE SUMMARY: Specific drug targets for breast ductal carcinoma in situ (DCIS) remain elusive, despite increasing disease prevalence and burden to healthcare services. Estrogen receptor (ER)-negative HER2-positive DCIS, associated with the poorest patient prognosis, is in particular need of novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Yvonne E., Wang, Guannan, Flynn, Ciara L., Madden, Stephen F., MacEneaney, Owen, Cruz, Rodrigo G. B., Richards, Cathy E., Jahns, Hanne, Brennan, Marian, Cremona, Mattia, Hennessy, Bryan T., Sheehan, Katherine, Casucci, Alexander, Sani, Faizah A., Hudson, Lance, Fay, Joanna, Vellanki, Sri H., O’Flaherty, Siobhan, Devocelle, Marc, Hill, Arnold D. K., Brennan, Kieran, Sukumar, Saraswati, Hopkins, Ann M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909510/
https://www.ncbi.nlm.nih.gov/pubmed/35267611
http://dx.doi.org/10.3390/cancers14051303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909510/
https://www.ncbi.nlm.nih.gov/pubmed/35267611
http://dx.doi.org/10.3390/cancers14051303

Ejemplares similares